Vivimed Labs Ltd

Vivimed Labs. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Vivimed Labs Ltd

₹ 4.95 -1.00%
31 Jul 2023
vivimedlabs.com BSE: 532660
About

Vivimed Labs Ltd is primarily engaged in the business of APIs, CDMO, Finished Dosage Formulation, Specialty Chemicals and retail branded formulation manufacturing.[1]

Key Points

API Division (~69% of revenues)[1]
This is the flagship division of the company which is primarily managed by its subsidiary UQUIFA s.a. based in Spain. The division further has 2 sub-divisions :-[2]

Website BSE
  • Market Cap ₹ 41.0 Cr.
  • Current Price ₹ 4.95
  • High / Low ₹ 6.97 / 4.85
  • Stock P/E
  • Book Value ₹ 21.3
  • Dividend Yield 0.00 %
  • ROCE -51.5 %
  • ROE -163 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Stock is trading at 0.23 times its book value

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -30.9% over past five years.
  • Promoter holding is low: 20.9%
  • Company has a low return on equity of -43.7% over last 3 years.
  • Contingent liabilities of Rs.123 Cr.
  • Promoters have pledged 37.1% of their holding.
  • Debtor days have increased from 110 to 150 days.
  • Promoter holding has decreased over last 3 years: -11.9%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
278 39 65 54 57 61 50 44 56 37 35 34 41
300 55 54 65 64 62 59 54 61 201 36 40 40
Operating Profit -22 -16 11 -10 -7 -1 -9 -9 -5 -164 -0 -6 1
OPM % -8% -42% 17% -19% -13% -2% -17% -21% -9% -444% -1% -18% 3%
4 2 1 0 -0 1 0 0 0 1 0 2 0
Interest 16 9 10 9 12 10 9 9 9 9 11 12 13
Depreciation 17 4 5 4 4 5 4 4 4 96 5 5 5
Profit before tax -50 -28 -2 -23 -24 -16 -22 -22 -18 -268 -16 -20 -17
Tax % 1% 2% 0% 0% 0% -18% 0% 0% 0% 1% 0% 0% 3%
-50 -27 -2 -23 -24 -18 -22 -22 -18 -266 -16 -20 -16
EPS in Rs -5.98 -3.31 -0.28 -2.81 -2.86 -2.21 -2.68 -2.66 -2.21 -32.08 -1.88 -2.45 -1.94
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
668 1,109 1,351 1,380 1,346 1,462 1,186 1,315 1,059 861 237 187 147
538 916 1,139 1,156 1,111 1,057 971 1,135 1,049 830 245 374 317
Operating Profit 130 193 212 224 234 404 215 180 10 32 -8 -187 -169
OPM % 20% 17% 16% 16% 17% 28% 18% 14% 1% 4% -3% -100% -115%
3 12 8 6 11 8 10 23 8 10 1 1 3
Interest 28 48 67 86 84 68 82 70 61 56 40 36 44
Depreciation 27 59 66 66 61 58 56 67 67 56 18 108 110
Profit before tax 78 98 87 78 100 286 86 66 -109 -70 -65 -331 -321
Tax % 19% 15% 24% 7% 16% 25% 11% 13% 0% -3% -4% 1%
63 84 66 72 84 214 76 57 -109 -72 -68 -329 -318
EPS in Rs 9.06 10.41 8.20 8.90 10.33 26.41 9.44 6.95 -13.16 -8.67 -8.16 -39.62 -38.35
Dividend Payout % 7% 6% 7% 0% 0% 2% 4% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: -16%
5 Years: -31%
3 Years: -44%
TTM: -30%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -293%
Stock Price CAGR
10 Years: -21%
5 Years: -27%
3 Years: -49%
1 Year: -24%
Return on Equity
10 Years: 0%
5 Years: -22%
3 Years: -44%
Last Year: -163%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 14 16 16 16 16 16 17 17 17 17 17 17 17
Reserves 328 427 478 479 505 718 885 602 493 415 348 23 160
Preference Capital 131 64 64 64 64 0 325 325 325 0 0 0
564 665 894 1,012 951 1,011 824 955 943 326 359 379 320
393 468 470 391 583 317 668 756 758 532 543 651 714
Total Liabilities 1,299 1,577 1,858 1,898 2,055 2,062 2,394 2,329 2,210 1,289 1,266 1,069 1,210
595 709 808 813 814 879 1,035 965 1,045 502 520 436 522
CWIP 8 27 38 90 94 76 65 122 89 60 40 21 21
Investments 1 0 0 3 3 3 3 3 86 199 199 199 192
695 840 1,011 992 1,144 1,104 1,290 1,239 990 529 507 414 476
Total Assets 1,299 1,577 1,858 1,898 2,055 2,062 2,394 2,329 2,210 1,289 1,266 1,069 1,210

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
45 90 -118 140 154 58 21 422 80 567 28 35
-424 -170 -291 -107 -190 -68 -164 -89 -196 404 -16 -5
404 67 419 -42 41 35 186 -338 72 -1,015 -10 -34
Net Cash Flow 25 -12 11 -8 4 25 44 -5 -44 -44 1 -3

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 121 101 94 87 88 50 85 99 86 46 134 150
Inventory Days 268 247 249 244 294 329 411 397 396 263 573 216
Days Payable 170 118 106 107 98 122 154 207 179 35 100 93
Cash Conversion Cycle 220 230 237 224 285 258 342 288 303 274 607 273
Working Capital Days 208 161 159 146 169 151 239 161 216 190 653 588
ROCE % 14% 13% 12% 11% 12% 22% 9% 7% -3% -1% -3% -52%

Shareholding Pattern

Numbers in percentages

Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
28.57% 28.57% 28.57% 28.57% 21.98% 20.96% 20.96% 20.96% 20.94% 20.94% 20.94% 20.94%
3.10% 2.66% 1.85% 1.64% 1.64% 1.64% 1.64% 1.64% 1.64% 1.64% 1.64% 1.64%
0.12% 0.12% 0.12% 0.12% 0.12% 0.12% 0.12% 0.12% 0.12% 0.12% 0.12% 0.12%
68.21% 68.65% 69.47% 69.67% 76.27% 77.29% 77.28% 77.29% 77.30% 77.30% 77.29% 77.30%
No. of Shareholders 37,98951,96350,92852,07453,11053,37652,39851,02650,68349,50349,03849,027

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls